KARMANOS CANCER HOSPITAL
The Sunshine Act requires manufacturers to report payments to teaching hospitals as institutions, separately from payments to individual physicians. These figures are money reported to the hospital itself — most of it research funding and grants, not compensation to any named doctor.
- Total reported
- $72.5M
- Transactions
- 13,802
- Companies
- 40
- Average per transaction
- $5,251
Who reported the payments
| Merck | $12,038,361 |
| Alkermes, Inc. | $8,029,055 |
| Regeneron | $5,181,609 |
| Janssen Research & Development, LLC | $4,153,990 |
| Genentech, Inc. | $3,447,049 |
| Astrazeneca UK Limited | $2,840,437 |
| Genmab U.S., Inc. | $2,698,017 |
| AstraZeneca | $2,641,839 |
| Bristol Myers Squibb | $2,497,581 |
| Pfizer | $2,442,109 |
| E.r. Squibb & Sons, L.L.C. | $1,918,863 |
| Exelixis Inc. | $1,829,086 |
| Bayer | $1,555,068 |
| Aadi Bioscience, Inc. | $1,540,314 |
| Takeda Pharmaceuticals U.S.A., Inc. | $1,389,439 |
| Tesaro, Inc. | $1,382,357 |
| Seagen Inc. | $1,303,580 |
| Gilead | $1,243,248 |
| Daiichi Sankyo Inc. | $1,120,253 |
| Pharmacyclics LLC, An Abbvie Company | $958,702 |
| Incyte Corporation | $918,869 |
| Eli Lilly | $734,293 |
| Mirati Therapeutics, Inc. | $673,372 |
| AbbVie | $654,148 |
| Bioverativ Therapeutics Inc. | $609,400 |
| National Marrow Donor Program | $580,944 |
| Coherus Oncology, Inc. | $557,960 |
| Boehringer Ingelheim | $514,000 |
| Novartis | $442,606 |
| Eisai Inc. | $430,398 |
| Radius Health, Inc. | $380,262 |
| EMD Serono, Inc. | $339,444 |
| Iovance Biotherapeutics, Inc. | $308,013 |
| Clovis Oncology, Inc. | $272,266 |
| Karyopharm Therapeutics Inc. | $264,230 |
| Boehringer Ingelheim International GmbH | $250,271 |
| CSL Behring | $246,498 |
| Corcept Therapeutics | $238,664 |
| Teva Pharmaceuticals USA, Inc. | $188,007 |
| Novocure Inc. | $183,401 |